We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

POC Blood Test Analyzer Performs CBC in Five Minutes

By LabMedica International staff writers
Posted on 23 May 2022
Print article
Image: HemoScreen POC blood test analyzer makes testing simple and accessible anywhere (Photo courtesy of PixCell Medical)
Image: HemoScreen POC blood test analyzer makes testing simple and accessible anywhere (Photo courtesy of PixCell Medical)

The world's first and only lab-quality, portable plug-and-play Complete Blood Count (CBC) analyzer allows real-time blood testing to be performed by anyone, anywhere, providing critical health data on the spot. This facilitates fast diagnostic results and data-driven disease management decisions.

PixCell Medical Technologies, Ltd.’s (Yokne'am Illit, Israel) HemoScreen hematology analyzer is the only 5-part differential CBC analyzer that is FDA-cleared, CE-marked and TGA-approved for point-of-care use offers clinically proven lab-accurate readings of 20 standard blood count parameters within five minutes, with just one finger-prick of blood. PixCell's HemoScreen delivers lab-accurate diagnostic information that alloes healthcare professionals to make rapid and clinically reliable decisions supported by real-time data.

The portable point of care hematology analyzer combines flow cytometry and digital imaging in a single platform for CBC and WBC 5-part differential. HemoScreen employs a patented, disposable cartridge preloaded with all necessary reagents. This reduces reagent waste and eliminates the need for maintenance and calibration, providing CBC results as well as comprehensive abnormal cell flagging for earlier detection of infection and certain cancer types.

“PixCell has transformed routine blood testing by combining novel microfluidics, machine learning and AI into a point-of-care instrument that anyone can operate,” said Dr. Avishay Bransky, co-founder and CEO of PixCell Medical. “Our breakthrough technology is allowing lab-grade testing to become independent from central laboratories and highly skilled experts, putting data in the hands of the medical staff who need it most, when they need it and where they need it.”

Related Links:
PixCell Medical Technologies, Ltd. 

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Respiratory Bacterial Panel
Real Respiratory Bacterial Panel 2
New
Bordetella Pertussis Molecular Assay
Alethia Pertussis

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.